Disseminated tumor cells in bone marrow following definitive radiotherapy for intermediate or high-risk prostate cancer

Prostate

Volumn 68, Issue 15, 2008, Pages 1607-1614

  Berg, Arne ^a,c   Bruland, Øyvind S ^a,b   Fossa, Sophie D ^a,b   Nesland, Jahn M ^a,b   Berner, Aasmund ^b   Schirmer, Cecilie ^b   Lilleby, Wolfgang ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Cytokeratin; Disease progression; Immunocytochemistry; Metastasis; Prostate specific antigen

Indexed keywords

CYTOKERATIN AE1; CYTOKERATIN AE3; CYTOKERATIN ANTIBODY; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ARTICLE; BONE MARROW; BONE MARROW BIOPSY; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED STUDY; DISSEMINATED TUMOR CELL; HORMONAL THERAPY; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MORPHOLOGICAL TRAIT; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; SAMPLING; TESTOSTERONE BLOOD LEVEL; TUMOR CELL; COMPARATIVE STUDY; DISEASE COURSE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; RISK ASSESSMENT; STAINING; TIME;

AGED; BONE MARROW; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; PROSTATIC NEOPLASMS; RISK ASSESSMENT; STAINING AND LABELING; TIME FACTORS;

EID: 55249111867     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20826     Document Type: Article

References (45)

1. Thames H, Kuban D, Levy L, Horwitz EM, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandier H, Shipley W, Zelefsky M, Zietman A. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys 2003;57:929-943.
2. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer 2004;4:448-456.
3. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber B, Gebauer G, Pierga JY, Marth C, Oruzio D, Wieds wang G, Solomayer EF, Kundt G, Strobl B, Fehm T, Wong GY, Bliss J, Vincent-Salomon A, Pantel K. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005;353:793-802.
4. Bruland OS, Hoifodt H, Saeter G, Smeland S, Fodstad O. Hematogenous micrometastases in osteosarcoma patients. Clin Cancer Res 2005;11:4666-4673.
5. Cote RJ, Beattie EJ, Chaiwun B, Shi SR, Harvey J, Chen SC, Sherrod AE, Groshen S, Taylor CR. Detection of occult bone marrow micrometastases in patients with operable lung carcinoma. Ann Surg 1995;222:415-423.
6. Faye RS, Aamdal S, Hoifodt HK, Jacobsen E, Holstad L, Skovlund E, Fodstad O. Immunomagnetic detection and clinical significance of micrometastatic tumor cells in malignant melanoma patients. Clin Cancer Res 2004;10:4134-4139.
7. Lindemann F, Schlimok G, Dirschedl P, Witte J, Riethmuller G. Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet 1992;340:685-689.
8. Pantel K. Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet 1996;347:649-653.
9. Berg A, Berner A, Lilleby W, Bruland OS, Fossa SD, Nesland JM, Kvalheim G. Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy. Int J Cancer 2007;120:1603-1609.
10. Weckermann D, Muller P, Wawroschek F, Harzmann R, Riethmuller G, Schlimok G. Disseminated cytokeratin positive tumor cells in the bone marrow of patients with prostate cancer: detection and prognostic value. J Urol 2001;166:699-703.
11. Drageset V, Nesland JM, Erikstein B, Skovlund E, Sommer H, Anker G, Wist E, Lundgren S, Bergh J, Kvalheim G. Monitoring of disseminated tumor cells in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy. Int J Cancer 2006;118:2877-2881.
12. Lilleby W, Nesland JM, Fossa SD, Torlakovic G, Waehre H, Kvalheim G. The prognostic impact of cytokeratin-positive cells in bone marrow of patients with localized prostate cancer. Int J Cancer 2003;103:91-96.
13. Pantel K, Enzmann T, Kollermann J, Caprano J, Riethmuller G, Kollermann MW. Immunocytochemical monitoring of micrometastatic disease: Reduction of prostate cancer cells in bone marrow by androgen deprivation. Int J Cancer 1997;71:521-525.
14. Wiedswang G, Borgen E, Karesen R, Qvist H, Janbu J, Kvalheim G, Nesland JM, Naume B. Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome. Clin Cancer Respondent 2004;10:5342-5348.
15. Pfitzenmaier J, Ellis WJ, Hawley S, Arfman EW, Klein JR, Lange PH, Vessella RL. The detection and isolation of viable prostate-specific antigen positive epithelial cells by enrichment: A comparison to standard prostate-specific antigen reverse transcriptase polymerase chain reaction and its clinical relevance in prostate cancer. Urol Oncol 2007;25:214-220.
16. Pickles T, Kim-Sing C, Morris WJ, Tyldesley S, Paltiel C. Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias. Int J Radiat Oncol Biol Phys 2003;57:11-18.
17. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005;29:1228-1242.
18. Mostofi FK, Davis CJ Jr, Sesterhenn IA. Pathology of carcinoma of the prostate. Cancer 1992;70:235-253.
19. Paus E, Nilsson O, Bormer OP, Fossa SD, Otnes B, Skovlund E. Stability of free and total prostate specific antigen in serum from patients with prostate carcinoma and benign hyperplasia. J Urol 1998;159:1599-1605.
20. Paus E, Nustad K, Bormer OP. Epitope mapping and affinity estimation of 83 antibodies against prostate-specific antigen. Tumour Biol 1999;20 (Suppl 1):52-69.
21. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-974.
22. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez TJ, Pfeffer JR, Lino CC, Zurlo A, Pierart M. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase in randomised trial. Lancet 2002;360:103-106.
23. Borgen E, Naume B, Nesland JM, Kvalheim G, Beiske K, Fodstad O, Diel I, Solomayer EF, Theocharous P, Coombes RC, Smith BM, Wunder E, Marolleau JP, Garcia J, Pantel K. Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy 1999;1:377-388.
24. Naume B, Borgen E, Kvalheim G, Karesen R, Qvist H, Sauer T, Kumar T, Nesland JM. Detection of isolated tumor cells in bone marrow in early-stage breast carcinoma patients: Comparison with preoperative clinical parameters and primary tumor characteristics. Clin Cancer Res 2001;7:4122-4129.
25. Borgen E, Naume B, Nesland JM, Nowels KW, Pavlak N, Ravkin I, Goldbard S. Use of automated microscopy for the detection of disseminated tumor cells in bone marrow samples. Cytometry 2001;46:215-221.
26. Berg A, Lilleby W, Bruland OS, Fossa SD. 10-year survival and quality of life in patients with high-risk PN0 prostate cancer following definitive radiotherapy. Int J Radiat Oncol Biol Phys 2007;69:1074-1083.
27. Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S, Spangberg A, Busch C, Nordling S, Garmo H, Palmgren J, Adami HO, Norlen BJ, Johansson JE. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005;352:1977-1984.
28. Haustermans KM, Hofland I, Van PH, Oyen R, Van d V, Begg AC, Fowler JF. Cell kinetic measurements in prostate cancer. Int J Radiat Oncol Biol Phys 1997;37:1067-1070.
29. Wiedswang G. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol 2003;21:3469-3478.
30. Mueller P, Carroll P, Bowers E, Moore D, Cher M, Presti J, Wessman M, Pallavicini MG. Low frequency epithelial cells in bone marrow aspirates from prostate carcinoma patients are cytogenetically aberrant. Cancer 1998;83:538-546.
31. Solakoglu O. Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors. Proc Natl Acad Sci USA 2002;99:2246-2251.
32. Zelefsky MJ, Yamada Y, Fuks Z, Zhang Z, Hunt M, Cahlon O, Park J, Shippy A. Long-term results of conformal radiotherapy for prostate cancer: Impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 2008;71:1028-1033.
33. Kestin LL, Goldstein NS, Vicini FA, Mitchell C, Gustafson GS, Stromberg JS, Chen PY, Martinez AA. Pathologic evidence of dose-response and dose-volume relationships for prostate cancer treated with combined external beam radiotherapy and high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2002;54:107-118.
34. Vance W, Tucker SL, de Crevoisier R, Kuban DA, Cheung MR. The predictive value of 2-year posttreatment biopsy after prostate cancer radiotherapy for eventual biochemical outcome. Int J Radiat Oncol Biol Phys 2007;67:828-833.
35. Willipinski-Stapelfeldt B, Riethdorf S, Assmann V, Woelfle U, Rau T, Sauter G, Heukeshoven J, Pantel K. Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res 2005;11:8006-8014.
36. Vessella RL, Pantel K, Mohla S. Tumor cell dormancy: An NCI workshop report. Cancer Biol Ther 2007;6:1496-1504.
37. Bianco FJ, Jr., Wood DP, Jr., Gomes de OJ, Nemeth JA, Beaman AA, Cher ML. Proliferation of prostate cancer cells in the bone marrow predicts recurrence in patients with localized prostate cancer. Prostate 2001;49:235-242.
38. Pfitzenmaier J, Ellis WJ, Arfman EW, Hawley S, McLaughlin PO, Lange PH, Vessella RL. Telomerase activity in disseminated prostate cancer cells. BJU Int 2006;97:1309-1313.
39. Naume B, Borgen E, Nesland JM, Beiske K, Gilen E, Renolen A, Ravnas G, Qvist H, Karesen R, Kvalheim G. Increased sensitivity for detection of micrometastases in bone-marrow/peripheral-blood stem-cell products from breast-cancer patients by negative immunomagnetic separation. Int J Cancer 1998;78:556-560.
40. Borgen E, Pantel K, Schlimok G, Muller P, Otte M, Renolen A, Ehnle S, Coith C, Nesland JM, Naume B. A European interlaboratory testing of three well-known procedures for immunocytochemical detection of epithelial cells in bone marrow. Results from analysis of normal bone marrow. Cytometry B Clin Cytom 2006;70:400-409.
41. Wiedswang G, Borgen E, Karesen R, Naume B. Detection of isolated tumor cells in BM from breast-cancer patients: Significance of anterior and posterior iliac crest aspirations and the number of mononuclear cells analyzed. Cytotherapy 2003;5:40-45.
42. Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, Lilja H, Schwartz L, Larson S, Fleisher M, Scher HI. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 2007;13:7053-7058.
43. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781-791.
44. Wiedswang G, Borgen E, Schirmer C, Karesen R, Kvalheim G, Nesland JM, Naume B. Comparison of the clinical significance of occult tumor cells in blood and bone marrow in breast cancer. Int J Cancer 2006;118:2013-2019.
45. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, Ryan P, Balis UJ, Tompkins RG, Haber DA, Toner M. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007;450:1235-1239.